A step closer to personalized chemotherapy: Consideration of the influence of genetic variation in hepatic uptake transporters on the metabolism of CYP3A substrates

Clinical Pharmacology and Therapeutics

Volumn 92, Issue 5, 2012, Pages 551-552

  Benet, L Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; ERYTHROMYCIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER;

CANCER CHEMOTHERAPY; COLON CARCINOMA; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG UPTAKE; ENZYME SUBSTRATE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MULTIDRUG RESISTANCE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; UPREGULATION;

ANIMALS; ANTI-BACTERIAL AGENTS; ERYTHROMYCIN; FEMALE; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT;

EID: 84867792005     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.165     Document Type: Review

References (10)

1. Benet, L.Z. A Holy Grail of clinical pharmacology: prediction of drug pharmacokinetics and pharmacodynamics in the individual patient. Clin. Pharmacol. Ther. 86, 133-134 (2009).
2. Opdam, F.L., Gelderblom, H. & Guchelaar, H.J. Phenotyping drug disposition in oncology. Cancer Treat. Rev. 38, 715-725 (2012).
3. Lancaster, C.S. et al. OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin. Pharmacol. Ther. 92, 642-650 (2012).
4. Wacher, V.J., Wu, C.Y. & Benet, L.Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 13, 129-134 (1995).
5. Schuetz, E.G., Beck, W.T. & Schuetz, J.D. Modulators and substrates of P-glycoprotein and cytochrome P450 3A coordinately upregulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49, 311-318 (1996). (Pubitemid 26066117)
6. Schuetz, E.G., Schinkel, A.H., Relling, M.V. & Schuetz, J.D. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P450 3A in mice and humans. Proc. Natl. Acad. Sci. USA 93, 4001-4005 (1996). (Pubitemid 26144235)
7. Baker, S.D. et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin. Cancer Res. 10, 8341-8350 (2004). (Pubitemid 40053395)
8. Benet, L.Z. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol. Interv. 5, 79-83 (2005) (Pubitemid 40590507)
9. Kurnik, D., Wood, A.J. & Wilkinson, G.R. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin. Pharmacol. Ther. 80, 228-234 (2006). (Pubitemid 44301092)
10. Frassetto, L.A., Poon, S., Tsourounis, C., Valera, C. & Benet, L.Z. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin. Pharmacol. Ther. 81, 828-832 (2007). (Pubitemid 46788293)